Journal article
Pro-Permeability Factors After Dexamethasone Implant in Retinal Vein Occlusion; the Ozurdex for Retinal Vein Occlusion (ORVO) Study
American journal of ophthalmology, Vol.160(2), pp.313-321.e19
08/2015
DOI: 10.1016/j.ajo.2015.04.025
PMCID: PMC6600806
PMID: 25908486
Abstract
To correlate aqueous vasoactive protein changes with macular edema after dexamethasone implant in retinal vein occlusion (RVO). Prospective, interventional case series. Twenty-three central RVO (CRVO) and 17 branch RVO (BRVO) subjects with edema despite prior anti-vascular endothelial growth factor (VEGF) treatment had aqueous taps at baseline and 4 and 16 weeks after dexamethasone implant. Best-corrected visual acuity (BCVA) and center subfield thickness were measured every 4 weeks. Aqueous vasoactive protein levels were measured by protein array or enzyme-linked immunosorbent assay. Thirty-two vasoactive proteins were detected in aqueous in untreated eyes with macular edema due to RVO. Reduction in excess foveal thickness after dexamethasone implant correlated with reduction in persephin and pentraxin 3 (Pearson correlation coefficients = 0.682 and 0.638, P = .014 and P = .003). Other protein changes differed among RVO patients as edema decreased, but ≥50% of patients showed reductions in hepatocyte growth factor, endocrine gland VEGF, insulin-like growth factor binding proteins, or endostatin by ≥30%. Enzyme-linked immunosorbent assay in 18 eyes (12 CRVO, 6 BRVO) showed baseline levels of hepatocyte growth factor and VEGF of 168.2 ± 20.1 pg/mL and 78.7 ± 10.0 pg/mL, and each was reduced in 12 eyes after dexamethasone implant. Dexamethasone implants reduce several pro-permeability proteins providing a multitargeted approach in RVO. No single protein in addition to VEGF can be implicated as a contributor in all patients. Candidates for contribution to chronic edema in subgroups of patients that deserve further study include persephin, hepatocyte growth factor, and endocrine gland VEGF.
Details
- Title: Subtitle
- Pro-Permeability Factors After Dexamethasone Implant in Retinal Vein Occlusion; the Ozurdex for Retinal Vein Occlusion (ORVO) Study
- Creators
- Peter A Campochiaro - The Wilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore, Maryland. Electronic address: pcampo@jhmi.eduGulnar Hafiz - The Wilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore, MarylandTahreem A Mir - The Wilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore, MarylandAdrienne W Scott - The Wilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore, MarylandRaafay Sophie - The Wilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore, MarylandSyed M Shah - The Wilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore, MarylandHoward S Ying - The Wilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore, MarylandLili Lu - The Wilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore, MarylandConnie Chen - The Wilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore, MarylandJ Peter Campbell - The Wilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore, MarylandSaleema Kherani - The Wilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore, MarylandIngrid Zimmer-Galler - The Wilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore, MarylandAdam Wenick - The Wilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore, MarylandIan Han - The Wilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore, MarylandYannis Paulus - The Wilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore, MarylandAkrit Sodhi - The Wilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore, MarylandGuohua Wang - The Wilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore, MarylandJiang Qian - The Wilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore, Maryland
- Resource Type
- Journal article
- Publication Details
- American journal of ophthalmology, Vol.160(2), pp.313-321.e19
- DOI
- 10.1016/j.ajo.2015.04.025
- PMID
- 25908486
- PMCID
- PMC6600806
- NLM abbreviation
- Am J Ophthalmol
- ISSN
- 1879-1891
- eISSN
- 1879-1891
- Publisher
- United States
- Grant note
- P30 EY001765 / NEI NIH HHS EY01765 / NEI NIH HHS
- Language
- English
- Date published
- 08/2015
- Academic Unit
- Ophthalmology and Visual Sciences
- Record Identifier
- 9983980069602771
Metrics
24 Record Views